Treatment and prevention of malaria in children

Area of Science:

• Global Health
• Infectious Diseases
• Pediatrics

Background:

• Malaria significantly impacts children under five, causing substantial mortality from Plasmodium falciparum in Africa and severe anemia from Plasmodium vivax in Asia.
• Suboptimal pediatric dosing for key antimalarials like artesunate and dihydroartemisinin-piperaquine has been identified.
• Emerging antimalarial resistance in Plasmodium falciparum, particularly in the Greater Mekong Subregion, poses a threat to global malaria control.

Purpose of the Study:

• To review current challenges and advancements in pediatric malaria treatment and prevention.
• To evaluate novel strategies including combination therapies, vaccines, and chemoprevention.
• To address safety concerns with existing treatments, such as primaquine for Plasmodium vivax.

Main Methods:

• Review of recent clinical findings and ongoing research in pediatric malaria.
• Evaluation of data from pilot studies on the RTS,S/AS01 malaria vaccine.
• Analysis of outcomes from seasonal malaria chemoprevention programs.
• Assessment of safety studies for escalated primaquine dosing regimens.

Main Results:

• Suboptimal pediatric dosing for several antimalarial agents has been corrected.
• Triple antimalarial combination therapies are under investigation to combat resistance.
• The RTS,S/AS01 vaccine shows partial protection and is in large-scale pilot evaluations.
• Seasonal malaria chemoprevention demonstrates success in reducing malaria incidence and mortality.

Conclusions:

• Ongoing research is crucial for optimizing pediatric malaria treatment and prevention.
• Combination therapies and vaccines offer promising complementary strategies.
• Safe and effective management of Plasmodium vivax relapses, particularly in children with G6PD deficiency, remains a key research area.